Thema: News: PCV als GBM-Rezidiv-Therapie
News: PCV als GBM-Rezidiv-Therapie
Tom[a]
30.08.2001 19:19:29
Neurology 2001;56:118-120
PCV chemotherapy for recurrent glioblastoma multiforme
A.C. Kappelle, MD;, T.J. Postma, MD;, M.J.B. Taphoorn, MD;, G.J. Groeneveld, MD;, M.J. van den Bent, MD;, C.J. van Groeningen, MD;, B.A. Zonnenberg, MD;, K.C.A. Sneeuw, MSc and J.J. Heimans, MD
From the Departments of Neurology and Medical Oncology (Drs. Kappelle, Postma, van Groeningen, and Heimans), University Hospital Vrije Universiteit, Amsterdam; Departments of Neurology and Medical Oncology (Drs. Taphoorn, Groeneveld, and Zonnenberg) University Medical Center, Utrecht; Department of Neuro-oncology (Dr. van den Bent) University Hospital Rotterdam/Daniel Den Hoed Cancer Center, Rotterdam; and Comprehensive Cancer Center (K.C.A. Sneeuw), Amsterdam, the Netherlands.
Address correspondence and reprint requests to Dr. T.J. Postma, Department of Neurology, University Hospital Vrije Universiteit, PO Box 7057, 1007 MB Amsterdam, the Netherlands; e-mail: TJ.Postma@azvu.nl
The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%).
In 16 patients (25%), stable disease was observed.
Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.
© 2001 American Academy of Neurology
PCV chemotherapy for recurrent glioblastoma multiforme
A.C. Kappelle, MD;, T.J. Postma, MD;, M.J.B. Taphoorn, MD;, G.J. Groeneveld, MD;, M.J. van den Bent, MD;, C.J. van Groeningen, MD;, B.A. Zonnenberg, MD;, K.C.A. Sneeuw, MSc and J.J. Heimans, MD
From the Departments of Neurology and Medical Oncology (Drs. Kappelle, Postma, van Groeningen, and Heimans), University Hospital Vrije Universiteit, Amsterdam; Departments of Neurology and Medical Oncology (Drs. Taphoorn, Groeneveld, and Zonnenberg) University Medical Center, Utrecht; Department of Neuro-oncology (Dr. van den Bent) University Hospital Rotterdam/Daniel Den Hoed Cancer Center, Rotterdam; and Comprehensive Cancer Center (K.C.A. Sneeuw), Amsterdam, the Netherlands.
Address correspondence and reprint requests to Dr. T.J. Postma, Department of Neurology, University Hospital Vrije Universiteit, PO Box 7057, 1007 MB Amsterdam, the Netherlands; e-mail: TJ.Postma@azvu.nl
The authors evaluated response, time to progression (TTP), survival, prognostic factors, and toxicity in 63 patients with a recurrent glioblastoma multiforme treated with procarbazine, lomustine, and vincristine (PCV) chemotherapy. Complete and partial response was observed in two (3%) and five patients (8%).
In 16 patients (25%), stable disease was observed.
Median TTP and survival were 13 and 33 weeks. Age < 40 years and Karnofsky Performance Status 90 were associated with longer TTP and survival. PCV treatment was generally well tolerated.
© 2001 American Academy of Neurology
Tom[a]
